{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:35:04Z","timestamp":1759336504468,"version":"build-2065373602"},"reference-count":7,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.nrl.2018.07.007","type":"journal-article","created":{"date-parts":[[2018,11,10]],"date-time":"2018-11-10T09:11:12Z","timestamp":1541841072000},"page":"521-522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["No se puede hablar de MELAS sin porcentaje de heteroplasmia ni investigaci\u00f3n multisist\u00e9mica"],"prefix":"10.1016","volume":"35","author":[{"given":"J.","family":"Finsterer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Maeztu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrl.2018.07.007_bib0040","article-title":"Global cerebral involvement and L-arginine use in a patient with MELAS syndrome","author":"P\u00e9rez Torre","year":"2018","journal-title":"Neurologia"},{"key":"10.1016\/j.nrl.2018.07.007_bib0045","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3858\/emm.2010.42.6.046","article-title":"Mutational analysis of whole mitochondrial DNA in patients with MELAS and MERRF diseases","volume":"42","author":"Choi","year":"2010","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.nrl.2018.07.007_bib0050","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/164_2016_2","article-title":"Toxicity of antiepileptic drugs to mitochondria","volume":"240","author":"Finsterer","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.nrl.2018.07.007_bib0055","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/BF02190669","article-title":"Stroke, hemiparesis and deficient mitochondrial beta-oxidation","volume":"153","author":"Vall\u00e9e","year":"1994","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.nrl.2018.07.007_bib0060","first-page":"1490181","article-title":"MELAS syndrome with cardiac involvement: A multimodality imaging approach","volume":"2016","author":"Seitun","year":"2016","journal-title":"Case Rep Cardiol"},{"key":"10.1016\/j.nrl.2018.07.007_bib0065","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.healun.2005.05.012","article-title":"Heart transplantation for progressive cardiomyopathy as a manifestation of MELAS syndrome","volume":"24","author":"Bhati","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.nrl.2018.07.007_bib0070","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/eurjhf\/hfp186","article-title":"Prevalence and natural history of heart disease in adults with primary mitochondrial respiratory chain disease","volume":"12","author":"Limongelli","year":"2010","journal-title":"Eur J Heart Fail"}],"container-title":["Neurolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485318302068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485318302068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:10:47Z","timestamp":1759324247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213485318302068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":7,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0213485318302068"],"URL":"https:\/\/doi.org\/10.1016\/j.nrl.2018.07.007","relation":{},"ISSN":["0213-4853"],"issn-type":[{"type":"print","value":"0213-4853"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No se puede hablar de MELAS sin porcentaje de heteroplasmia ni investigaci\u00f3n multisist\u00e9mica","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2018.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}